Literature DB >> 10600468

Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae.

J C Cook1, J G Joyce, H A George, L D Schultz, W M Hurni, K U Jansen, R W Hepler, C Ip, R S Lowe, P M Keller, E D Lehman.   

Abstract

Recombinant major capsid protein, L1 (M(r) = 55,000), of human papillomavirus type 11 was expressed intracellularly at high levels in a galactose-inducible Saccharomyces cerevisiae expression system by an HPV6/11 hybrid gene. The capsid protein self-assembled into virus-like particles (VLPs) and accounted for 15% of the total soluble protein. A purification process was developed that consisted of two main steps: microfiltration and cation-exchange chromatography. The purified VLPs were 98% homogeneous, and the overall purification yield was 10%. The final product was characterized by several analytical methods and was highly immunogenic in mice. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600468     DOI: 10.1006/prep.1999.1155

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  21 in total

1.  Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.

Authors:  N Hanumantha Rao; P Baji Babu; L Rajendra; R Sriraman; Yuk-Ying S Pang; John T Schiller; V A Srinivasan
Journal:  Vaccine       Date:  2011-07-29       Impact factor: 3.641

2.  Saccharomyces cerevisiae is permissive for replication of bovine papillomavirus type 1.

Authors:  Kong-Nan Zhao; Ian H Frazer
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 3.  Plant-derived virus-like particles as vaccines.

Authors:  Qiang Chen; Huafang Lai
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

4.  Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18.

Authors:  Dennis Dias; Jeff Van Doren; Sonela Schlottmann; Sheri Kelly; Derek Puchalski; Wanda Ruiz; Patricia Boerckel; Joseph Kessler; Joseph M Antonello; Tina Green; Martha Brown; Judith Smith; Narendra Chirmule; Eliav Barr; Kathrin U Jansen; Mark T Esser
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

Review 5.  Norwalk virus-like particles as vaccines.

Authors:  Melissa Herbst-Kralovetz; Hugh S Mason; Qiang Chen
Journal:  Expert Rev Vaccines       Date:  2010-03       Impact factor: 5.217

6.  Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants.

Authors:  Qiang Chen; Junyun He; Waranyoo Phoolcharoen; Hugh S Mason
Journal:  Hum Vaccin       Date:  2011-03-01

7.  Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy.

Authors:  Qinjian Zhao; Clinton S Potter; Bridget Carragher; Gabriel Lander; Jaime Sworen; Victoria Towne; Dicky Abraham; Paul Duncan; Michael W Washabaugh; Robert D Sitrin
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

8.  Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.

Authors:  Mayumi Nakagawa; Raphael Viscidi; Ian Deshmukh; Maria Da Costa; Joel M Palefsky; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

9.  Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types.

Authors:  O Martin Williams; Keith W Hart; Eddie C Y Wang; Colin M Gelder
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris.

Authors:  Silvia Boschi Bazan; Agtha de Alencar Muniz Chaves; Karina Araújo Aires; Aurora Marques Cianciarullo; Robert L Garcea; Paulo Lee Ho
Journal:  Arch Virol       Date:  2009-09-10       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.